BIOMAT Database Logo BIOMAT Database Logo

In vitro comparison activity of OPC-17116, a new fluoroquinolone, against more than 5,000 recent clinical isolates from five medical centers. 1993

H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
Department of Pathology, University of Iowa Hospital & Clinics, Iowa City 52242.

The in vitro activity of OPC-17116, a new fluoroquinolone, was compared with those of ciprofloxacin, ofloxacin and cefixime. A total of 5,231 fresh clinical isolates from five geographically separate US medical centers were tested. The primary results of this study are: 1. OPC-17116 is very active against Enterobacteriaceae [MIC90s, 0.015-1 microgram/ml, except Providencia rettgeri (MIC90, > 8 micrograms/ml)], 2. among nonenteric Gram-negative bacilli (e.g. Xanthomonas maltophilia, MIC90, 2 micrograms/ml) and Gram-positive cocci (e.g. oxacillin-susceptible staphylococci, MIC90s, 0.12-0.5 microgram/ml) OPC-17116 demonstrated higher activity than ciprofloxacin or ofloxacin, 3. the quinolones were more active than cefixime against most of the species tested, especially against Gram-positive and non-enteric Gram-negative organisms. The results of this study, associated with prior documented favorable qualities, support continued investigation of OPC-17116 for clinical use.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000890 Anti-Infective Agents Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. Anti-Infective Agent,Anti-Microbial Agent,Antimicrobial Agent,Microbicide,Microbicides,Anti-Microbial Agents,Antiinfective Agents,Antimicrobial Agents,Agent, Anti-Infective,Agent, Anti-Microbial,Agent, Antimicrobial,Agents, Anti-Infective,Agents, Anti-Microbial,Agents, Antiinfective,Agents, Antimicrobial,Anti Infective Agent,Anti Infective Agents,Anti Microbial Agent,Anti Microbial Agents
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D015363 Quinolones A group of derivatives of naphthyridine carboxylic acid, quinoline carboxylic acid, or NALIDIXIC ACID. Ketoquinoline,Ketoquinolines,Oxoquinoline,Oxoquinolines,Quinolinone,Quinolinones,Quinolone
D024841 Fluoroquinolones A group of QUINOLONES with at least one fluorine atom and a piperazinyl group. Fluoroquinolone

Related Publications

H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
In-vitro activity of OPC-17116 against more than 6000 consecutive clinical isolates: a multicentre international study.
March 1994, The Journal of antimicrobial chemotherapy,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
March 1995, Diagnostic microbiology and infectious disease,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
June 1997, The Journal of antimicrobial chemotherapy,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
In vitro activity of OPC-17116.
June 1992, Antimicrobial agents and chemotherapy,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
In vitro comparison of E4868, a new trifluoroquinolone, with ciprofloxacin and temafloxacin tested against 5192 recent clinical isolates from five medical centers.
January 1993, Diagnostic microbiology and infectious disease,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
In vitro comparative antimicrobial activity of cefpimizole against clinical isolates from five medical centers.
June 1985, Antimicrobial agents and chemotherapy,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
In-vitro activity of OPC-17116 against bacterial enteric pathogens.
September 1994, The Journal of antimicrobial chemotherapy,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
June 1994, Diagnostic microbiology and infectious disease,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments.
February 1995, The Journal of antimicrobial chemotherapy,
H S Sader, and R N Jones, and S D Allen, and E H Gerlach, and P R Murray, and J A Washington
Cefdinir (FK482), an orally administered cephalosporin in vitro activity comparison against recent clinical isolates from five medical centers and determination of MIC quality control guidelines.
August 1992, Diagnostic microbiology and infectious disease,
Copied contents to your clipboard!